View on Pubmed.gov 36070840 | View on doi.org 10.1016/j.trsl....
Inflammasome activation in traumatic brain injury and Alzheimer's disease.
- Department of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami, FL, USA.
- The Miami Project to Cure Paralysis, Miami, FL, USA; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Center for Cognitive Neuroscience and Aging, University of Miami Miller School of Medicine, Miami, FL, USA.
- The Miami Project to Cure Paralysis, Miami, FL, USA; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Bruce W. Carter Department of Veterans Affairs Medical Center, Miami, FL, USA.
- The Miami Project to Cure Paralysis, Miami, FL, USA; Department of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami, FL, USA.
- The Miami Project to Cure Paralysis, Miami, FL, USA; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Center for Cognitive Neuroscience and Aging, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: ddietrich@med.miami.edu.
Abstract
Traumatic brain injury (TBI) and Alzheimer's disease (AD) represent 2 of the largest sources of death and disability in the United States. Recent studies have identified TBI as a potential risk factor for AD development, and numerous reports have shown that TBI is linked with AD associated protein expression during the acute phase of injury, suggesting an interplay between the 2 pathologies. The inflammasome is a multi-protein complex that plays a role in both TBI and AD pathologies, and is characterized by inflammatory cytokine release and pyroptotic cell death. Products of inflammasome signaling pathways activate microglia and astrocytes, which attempt to resolve pathological inflammation caused by inflammatory cytokine release and phagocytosis of cellular debris. Although the initial phase of the inflammatory response in the nervous system is beneficial, recent evidence has emerged that the heightened inflammatory response after trauma is self-perpetuating and results in additional damage in the central nervous system. Inflammasome-induced cytokines and inflammasome signaling proteins released from activated microglia interact with AD associated proteins and exacerbate AD pathological progression and cellular damage. Additionally, multiple genetic mutations associated with AD development alter microglia inflammatory activity, increasing and perpetuating inflammatory cell damage. In this review, we discuss the pathologies of TBI and AD and how they are impacted by and potentially interact through inflammasome activity and signaling proteins. We discuss current clinical trials that target the inflammasome to reduce heightened inflammation associated with these disorders.
References
Cell Stress. 2018 Jun 29;2(7):150-161
J Neurosci. 2011 Jun 29;31(26):9513-25
Neurocrit Care. 2022 Apr;36(2):527-535
J Cereb Blood Flow Metab. 2009 Jul;29(7):1251-61
Cited by 53 citations (total)
Review Journal Article
Research progress of neuroinflammation-related cells in traumatic brain injury: A review.
Electronic publication date June 26, 2023
Qinghui Zhao [...] Jianhua Zhang et al.
Neuroinflammation after traumatic brain injury (TBI) is related to chronic neurodegenerative diseases and is one of the causes of acute...
Journal Article Review
An Expanded Narrative Review of Neurotransmitters on Alzheimer's Disease: The Role of Therapeutic Interventions on Neurotransmission.
Electronic publication date January 27, 2025
Enes Akyuz [...] Mohd Farooq Shaikh et al.
Alzheimer's disease (AD) is a progressive neurodegenerative disease. The accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles are the...
Conflict of interest statement
Conflicts of Interest JPdRV, HMB, RWK, and WDD are co-founders and managing members of InflamaCORE, LLC and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV, HMB, RWK, and WDD are Scientific Advisory Board Members of ZyVersa Therapeutics. NHJ declares no conflicts of interest.
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
Substances
- •
Copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.